Home Newsfeeds Morgan Stanley Downgrades StoneCo to Equal-Weight, Announces $15 Price Target

Morgan Stanley Downgrades StoneCo to Equal-Weight, Announces $15 Price Target

Morgan Stanley analyst Jorge Kuri downgrades StoneCo (NASDAQ:STNE) from Overweight to Equal-Weight and announces $15 price target.

byBenzinga Newsdesk

December 7, 2022

1 minute read

Morgan Stanley analyst Jorge Kuri downgrades StoneCo (NASDAQ:STNE) from Overweight to Equal-Weight and announces $15 price target.

What’s Going On With Nikola Corporation Stock?

By Erica Kollmann

November 3, 12:19 PM

Nikola Corporation (NASDAQ: NKLA) shares are trading higher Friday. The company reported its third-quarter financial results on Thursday. Here's a look at what's going on: What To Know:

NKLA

Texas Roadhouse Analysts Raise Their Forecasts Following Q4 Results

By Avi Kapoor

February 16, 8:50 AM

Texas Roadhouse (NASDAQ: TXRH) reported upbeat earnings for its fourth quarter on Thursday.

TXRH

Canaccord Genuity Maintains Hold on Edwards Lifesciences, Lowers Price Target to $91

By Benzinga Newsdesk

October 14, 7:53 AM

Canaccord Genuity analyst William Plovanic maintains Edwards Lifesciences (NYSE:EW) with a Hold and lowers the price target from $106 to $91.

CRISPR Therapeutics Announces Updates To Immuno-Oncology Pipeline And Expansion Into Autoimmune Disease

By Benzinga Newsdesk

December 4, 5:26 PM

-Based on preliminary data from ongoing clinical trials, focusing on next-generation CAR T product candidates, CTX112™ targeting CD19 and CTX131™ targeting CD70- -Expanding trials of CTX112 into

CRSP

Morgan Stanley Downgrades StoneCo to Equal-Weight, Announces $15 Price Target

Related Posts

What’s Going On With Nikola Corporation Stock?

Texas Roadhouse Analysts Raise Their Forecasts Following Q4 Results

Canaccord Genuity Maintains Hold on Edwards Lifesciences, Lowers Price Target to $91

CRISPR Therapeutics Announces Updates To Immuno-Oncology Pipeline And Expansion Into Autoimmune Disease